The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizing the signals into a 12-lead ECG. This platform ...

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis s ...

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submiss ...

The first patent pertains to the company’s cable-free three-dimensional (3D ... The captured signals are synthesised into a 12-lead ECG through a personalised transformational matrix.

It is mandatory that ECG abnormalities resulting from intensive physical training and those of a potential cardiac pathology are properly defined. This article provides a modern approach to ...

The purpose of this study was to evaluate whether the 12-lead ECG could be substituted by ECG sets with a limited number of leads. Materials and methods: The performance of three ECG systems (ie ...

A screenshot from a video demonstrating how to use the HeartBeam ECG device. HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its ...